Study of Olverembatinib (HQP1351) in Patients With CML-CP

Progression Free Survival (PFS) (Part B)

To evaluate duration of PFS (i.e., from the date of enrollment to the earliest occurrence of documented disease progression to AP/BP or the date of death from any cause) for olverembatinib in CML-CP patients with T315I mutation

Time frame: 5 years after the last patient received the first study dose

Overall Survival (OS) (Part A)

To compare OS (duration from date of randomization to date of death) for olverembatinib versus bosutinib

Time frame: 5 years after the last patient received the first study dose

Overall Survival (OS) (Part B)

To evaluate OS (duration from date of randomization to date of death) for olverembatinib in CML-CP patients with T315I mutation

Time frame: 5 years after the last patient received the first study dose

Number of participants with treatment-emergent and treatment-related adverse events as assessed by CTCAE v5.0 (Parts A and B)

According to CTCAE v5.0, the number and frequency of adverse events for test drug will be assessed.

Time frame: 96 weeks after the last patient received the first study dose

Characterization of population pharmacokinetics of olverembatinib (Parts A and B)

Blood samples will be collected to measure the plasma concentration of olverembatinib

Time frame: At the end of Cycle 1 and Cycle 2 (each cycle is 28 days)